Novo Nordisk A/s

Argos Therapeutics, Inc.

Inger Lund Pedersen

Peter Andreas Nicolai Reumert Wagtmann

Berit Olsen Krogh

Birgitte Friedrichsen

Soren Berg Padkjaer

Lars Anders Svensson

Anders Svensson

Birgitte Urso

Peter Andreas Wagtmann

Birgitte Ursø

Jan Fleckner

Birgitte UrsØ

Søren PADKJÆR

Birgitte Ursoe

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Antibodies against human NKG2D and uses thereof

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

The present invention provides humanized anti-human IFN-&#x3b1; monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.

Humanized antibodies against human interferon-alpha

Growing community of inventors

Vanløse, Denmark

Inger Lund Pedersen